Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Robert Musci
Observed name:
R Musci
ORCID:
0000-0002-6521-6967
Observed ORCID:
0000-0002-6521-6967
OpenAlex ID:
A5039351696
Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model
2022
·
Alexia Kieffer
, Matthieu Beuvelet
, et al.
·
The Journal of Infectious Diseases
·
90
PDF
Disease Burden Associated with All Infants in Their First RSV Season in the UK: A Static Model of Universal Immunization with Nirsevimab Against RSV-Related Outcomes
2024
·
Alexia Kieffer
, Matthieu Beuvelet
, et al.
·
Infectious Diseases and Therapy
·
19
PDF
Comparison of the public health impact of RSV disease prevention options for infants: a static decision model of the US birth cohort
2025
·
Alexia Kieffer
, Mehdi Ghemmouri
, et al.
·
Expert Review of Vaccines
·
11
PDF
Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study
2026
·
Benjamin Yarnoff
, Matthieu Beuvelet
, et al.
·
Infectious Diseases and Therapy
·
8
PDF
Estimating the Public Health and Economic Impact of Immunisation with Nirsevimab or Maternal Immunisation for the Prevention of RSV-Related Outcomes Over Infants’ First RSV Season in the UK
2025
·
Mersha Chetty
, Paul Costello
, et al.
·
Infectious Diseases and Therapy
·
4
PDF
Estimation of Public Health Impact with Use of Nirsevimab During the 2024–2025 RSV Season in the USA: a Modeling Study
2026
·
Benjamin Yarnoff
, Maureen P. Neary
, et al.
·
Pulmonary Therapy
·
3
PDF
[Prognostic predictive factors of the clinical response to immunotherapy with subcutaneous interleukin-2, in patients with metastatic renal carcinoma: analysis of 60 cases].
1995
·
P Lissoni
, E Scardino
, et al.
·
PubMed
·
3
Comment on Kura et al. Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States. Vaccines 2026, 14, 411
2026
·
Erin N. Hodges
, Mehdi Ghemmouri
, et al.
·
Vaccines
·
1
EE274 Estimated Costs of Adverse Event Management in NSCLC Patients with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations Treated with Amivantamab or Mobocertinib after Progression on Platinum-Based Chemotherapy
2022
·
P Vadagam
, J Vanderpoel
, et al.
·
Value in Health
·
1
Modeled cost of severe adverse events of first line amivantamab plus lazertinib or osimertinib plus chemotherapy in patients with treatment naïve EGFR-mutated advanced NSCLC.
2026
·
Alexander I. Spira
, Robert Musci
, et al.
·
JCO Oncology Practice
PDF
Cost-effectiveness and public health impact of RSV immunization for all infants in Japan: a mixed strategy with nirsevimab and RSVpreF
2026
·
Naruhiko Ishiwada
, Xinyu Wang
, et al.
·
Figshare
Cost-effectiveness and public health impact of RSV immunization for all infants in Japan: a mixed strategy with nirsevimab and RSVpreF
2026
·
Naruhiko Ishiwada
, Xinyu Wang
, et al.
·
Expert Review of Vaccines
Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy
2026
·
Alexander Spira
, Pratyusha Vadagam
, et al.
·
Journal of health economics and outcomes research
PDF
Response to Fullarton et al
2022
·
Alexia Kieffer
, Matthieu Beuvelet
, et al.
·
The Journal of Infectious Diseases
PDF
POSC256 Application of Progression-Free Survival As Surrogate Endpoint for Overall Survival in Nice Reviews of Advanced Breast Cancer Drugs
2022
·
D Zou
, A Sun
, et al.
·
Value in Health
Show more works
View as search
Works count:
15
Citation count:
140
H-index:
4
I10-index:
3
Year
Topic
Type